A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Gynecologic Oncology

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.YGYNO.2012.05.030PMID 22664059PMCID PMC4127485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

  2011cited by this paper
• Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia

  2011cited by this paper
• Abstract 4015: Flavopiridol-induced upregulation of HtrA1 is associated with suppression of its negative transcriptional regulator WT-1 and with enhanced chemosensitivity

  2011cited by this paper
• Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

  2010cited by this paper
• Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

  2010cited by this paper
• Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer

  2010cited by this paper
• Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.

  2010cited by this paper
• Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

  2009cited by this paper
• Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

  2009cited by this paper
• Treatment for Recurrent Ovarian Cancer—At First Relapse

  2009cited by this paper
• A Phase II Trial of Fixed-Dosed Rate Gemcitabine in Platinum-Resistant Ovarian Cancer: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial

  2008cited by this paper
• Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).

  2007cited by this paper
• Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy

  2007cited by this paper
• A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy

  2006cited by this paper
• Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

  2006cited by this paper
• Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

  2006cited by this paper
• A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

  2006cited by this paper
• Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

  2005cited by this paper
• A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer

  2004cited by this paper
• Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

  2004cited by this paper
• Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

  2004cited by this paper
• Clinical experience with topotecan in relapsed ovarian cancer.

  2003cited by this paper
• Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer.

  2002cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

  2000cited by this paper
• Flavopiridol binds to duplex DNA.

  2000cited by this paper
• Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

  1996cited by this paper
• The search for synergy: a critical review from a response surface perspective.

  1995cited by this paper
• Cancer statistics

  1989cited by this paper
• Analysis of combined drug effects: a new look at a very old problem

  1983cited by this paper
• Antineoplastic Agents: the Importance of Sequence of Administration'

  year unknowncited by this paper

• Promising new drugs and therapeutic approaches for treatment of ovarian cancer—targeting the hallmarks of cancer

  2025cites this paper
• Rapid P-TEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy

  2024cites this paper
• Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies.

  2024cites this paper
• Rapid PTEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy

  2023cites this paper
• Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125 Selective Agents.

  2022cites this paper
• Recent Insights into Therapeutic Potential of Plant-Derived Flavonoids against Cancer.

  2022cites this paper
• Programmed cell death, redox imbalance, and cancer therapeutics

  2021cites this paper
• Role of semisynthetic flavonoids on cytotoxic chemotherapy—Dual benefit to cancer patients?

  2021cites this paper
• Targeting cyclin-dependent kinase 9 in cancer therapy

  2021cites this paper
• CMAR_A_249540 10423..10437

  2020cites this paper
• The survivin molecule as a double‐edged sword in cellular physiologic and pathologic conditions and its role as a potential biomarker and therapeutic target in cancer

  2020cites this paper
• Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets

  2020cites this paper
• Simvastatin is a potential candidate drug in ovarian clear cell carcinomas

  2020influential citation
• Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer

  2020cites this paper
• Warburg Effect and its Role in Cancer Cell Metabolism: A Review

  2020cites this paper
• Hunting a Silent Killer. Biomolecular Approaches in Ovarian Cancer

  2019cites this paper
• Structure-based virtual screening and molecular docking for the identification of potential novel EGFRkinase inhibitors against ovarian cancer

  2019cites this paper
• Flavonoids as anticancer therapies: A systematic review of clinical trials

  2019influential citation
• Therapeutic strategies involving survivin inhibition in cancer

  2018cites this paper
• CDK9: A key player in cancer and other diseases

  2018cites this paper
• CDK inhibitors as anticancer agents: Current status and future prospective

  2017cites this paper
• Functional characterisation of VAV-interacting Krüppel-like factor (VIK) in breast cancer

  2017cites this paper
• An insight into the inhibitory selectivity of 4-(Pyrazol- 4-yl)-pyrimidines to CDK4 over CDK2

  2017cites this paper
• Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells

  2017cites this paper
• Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.

  2017cites this paper
• Re-Validation of New Develop Highly Sensitive, Simple LCMS/MS Method for the Estimation of Rohitukine and its Application in ADME/Pre-Clinical Pharmacokinetics

  2017cites this paper
• Optimization of the Synthesis of Flavone-Amino Acid and Flavone-Dipeptide Hybrids via Buchwald-Hartwig Reaction.

  2017cites this paper
• Cellular responses to replication stress: Implications in cancer biology and therapy.

  2017cites this paper
• Targeting Cyclin-Dependent Kinases in Ovarian Cancer

  2017cites this paper
• Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma

  2017cites this paper
• Targeting of CDK9 with indirubin 3’-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice

  2017cites this paper
• Flavopiridol Strongly Sensitizes Canine Lymphoma Cells to TRAIL-induced Apoptosis.

  2017cites this paper
• Targeting the hallmarks of ovarian cancer: The big picture.

  2016cites this paper
• Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.

  2016cites this paper
• Pathogenesis and heterogeneity of ovarian cancer

  2016cites this paper
• Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.

  2016cites this paper
• Screening of promising chemotherapeutic candidates from plants extracts

  2016cites this paper
• Overview of CDK9 as a target in cancer research

  2016cites this paper
• Docking and ADME/T analysis of silibinin as a potential inhibitor of EGFR kinase for ovarian cancer therapy -

  2016cites this paper
• Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

  2015cites this paper
• Recent Advances on Small-Molecule Survivin Inhibitors

  2015cites this paper
• Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment

  2015cites this paper
• Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression.

  2015cites this paper
• Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro

  2015cites this paper
• Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication

  2015cites this paper
• In silico analysis of indole-3-carbinol and its metabolite DIM as EGFR tyrosine kinase inhibitors in platinum resistant ovarian cancer vis a vis ADME/T property analysis

  2015cites this paper
• Buchwald-Hartwig reactions of monohaloflavones

  2015cites this paper
• Anticancer Drugs and Potential Anticancer Leads Inspired by Natural Products

  2015cites this paper
• Targeting metabolic reprogramming associated to cancer cells: search of novel targets and combined therapies in cancer treatment

  2015cites this paper
• Discovery of Novel Tubulin Polymerization Inhibitors and Survivin Inhibitors as Potential Anticancer Agents

  2015cites this paper
• Some natural sources of substances with antitumor effects

  2014cites this paper
• Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies

  2014cites this paper
• Target driven preclinical screening for new antimitotic chemotherapy agents.

  2014cites this paper
• CGP74514A enhances TRAIL-induced apoptosis in breast cancer cells by reducing X-linked inhibitor of apoptosis protein.

  2014cites this paper
• A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage

  2014cites this paper
• Ultrasound‐Assisted Synthesis, Anticonvulsant Activity, and Docking Study of Indole‐Appended Thiazolidin‐4‐ones

  2014cites this paper
• Pharmacokinetics, Tissue Distribution and Plasma Protein Binding Studies of Rohitukine: A Potent Anti-hyperlipidemic Agent

  2014cites this paper
• In Vitro and In Silico Studies to Explore Structural Features of Flavonoids for Aldehyde Oxidase Inhibition

  2014cites this paper
• Comparative drug screening in NUT midline carcinoma

  2014cites this paper
• Highlights of the Latest Advances in Research on CDK Inhibitors

  2014cites this paper
• Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.

  2013cites this paper
• Phytochemicals, microRNAs, and Cancer: Implications for Cancer Prevention and Therapy

  2013cites this paper
• Overactive Cdk2 in the progression and treatment of cancer

  2013cites this paper
• Mitochondria as Targets for Phytochemicals in Cancer Prevention and Therapy

  2013cites this paper
• Effects of alvocidib and carboplatin on ovarian cancer cells in vitro.

  2013cites this paper
• The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells

  2013cites this paper
• Targeting cell cycle regulation in cancer therapy.

  2013cites this paper
• Recent agents targeting HIF‐1α for cancer therapy

  2013cites this paper
• Candidate cancer-targeting agents identified by expression-profiling arrays

  2013cites this paper